Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 8/20 | 0.39 |
| ▸ | FUT6 | P51993 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523361 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL15215805 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL13522466 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL10819846 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL12202712 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL12149834 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL3132403 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL13522420 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL16350180 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E | |
| SCHEMBL12202710 | 1.00 | HINT1 (0.45) | HINT1TAS1R3TAS1R1ADORA3NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | IDENIX PHARMACEUTICALS, INC | 2009-07-02 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | HINT1 351/4885TAS1R3 4541/4885TAS1R1 4630/4885 |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | HAVCR2, PYGL, GYS2 | HINT1 337/4885TAS1R3 4760/4885TAS1R1 4791/4885 |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | HAVCR2, PYGL, GYS2 | HINT1 337/4885TAS1R3 4760/4885TAS1R1 4791/4885 |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GYS2 | HINT1 337/4885TAS1R3 4760/4885TAS1R1 4791/4885 |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | HINT1 337/4885TAS1R3 4760/4885TAS1R1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.